Search

Displaying results 7021 - 7030 of 7041 in total
  1. Drug

    CTB001

    go.drugbank.com/drugs/DB18316
    Investigational

    CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.[L48146]

  2. Drug

    LAVA-051

    go.drugbank.com/drugs/DB18395
    Investigational

    LAVA-051 is a humanized Vγ9Vδ2-T cell-engaging bispecific antibody.

  3. Drug

    ISB 2001

    go.drugbank.com/drugs/DB18570
    Investigational

    ISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3.

  4. Drug

    BG1805

    go.drugbank.com/drugs/DB18667
    Investigational

    BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.

  5. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  6. Drug

    NNC-55-0396 free base

    go.drugbank.com/drugs/DB17037
    Experimental

    NNC-55-0396 is a T-type Ca(2+) channel inhibitor.[A253047]

  7. Drug

    Gemogenovatucel-T

    go.drugbank.com/drugs/DB17412
    Investigational

    [A255163] Gemogenovatucel-T is being investigated in the treatment of various cancers. … Gemogenovatucel-T is a bi-shRNA furin/Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented autologous tumour cell vaccine.

    Synonyms: Gemogenovatucel-T
  8. Drug

    Erfonrilimab

    go.drugbank.com/drugs/DB17446
    Investigational

    Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

  9. Drug

    UCART22

    go.drugbank.com/drugs/DB17466
    Investigational

    UCART22 are allogeneic CD22-specific universal CAR-expressing T lymphocytes.

    Synonyms: Allogeneic gene-edited CAR T cells UCART22, Allogeneic TALEN gene-edited CAR T-Cells UCART22
  10. Drug

    CB-010

    go.drugbank.com/drugs/DB17711
    Investigational

    CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.[L46158]